Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Investor Presentation (August 2025)
36 slides from Century Therapeutics's investor presentation, Aug 14, 2025
Slide 1: Corporate Overview August 2025
Corporate Overview August 2025
Slide 2: Forward-looking statements
© 2025 2 2 This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statements t
Slide 3: Century Therapeutics Today
Estimated cash runway into 4Q27 ; Enhanced resources to enable key value milestones Enhanced precl inical pipeline and platform aiming to expand and multiply cell therapy value • Prioritizing development activities for CNTY - 308 for B - cell - mediated diseases • Selective expansion to non - immune
Slide 4: Clear differentiation from other allogeneic cell therapies with pathway to antibody-like scale
© 2025 4 4 Clear differentiation from other allogeneic cell therapies with pathway to antibody - like scale Century’s ability to create multiple iPSC - derived cell types incorporating Allo - Evasion stands apart from other allogeneic cell therapy approaches Engineerability • Control of differentiat
Slide 5: Allo-Evasion engineering aims to drive durable responses by enabling repeat dosing
© 2025 5 5 1. Company data: ELiPSE - 1 Phase 1 study in B - cell malignancies Allo - Evasion engineering aims to drive durable responses by enabling repeat dosing for tighter control over drug exposure Clinical data from CNTY - 101 in ELiPSE - 1 show persistent exposure in the presence of an intact
Slide 6: Continued evolution to enhance holistic protection from major immunity pathways
© 2025 6 6 Continued evolution to enhance holistic protection from major immunity pathways 1. https://www.centurytx.com/wp - content/uploads/ASH_Welstead_Universal - Protection - of - Allogenic - T - Cells - Final.pdf 2. https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.202
Slide 7: CD300a TASR ligand protects from host NK cells in preclinical studies
© 2025 7 7 https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024013436/518079/Universal - Protection - of - Allogeneic - T - Cell ; https:// www.centurytx.com /wp - content/uploads/ASH_Welstead_Universal - Protection - of - Allogenic - T - Cells - Final.pdf The CD300a TASR
Slide 8: IgG degrading enzyme protected cells from humoral immunity pathways
© 2025 8 8 WT Gen 2.3 0 25 50 75 100 Antibody-Dependent Cellular Cytotoxicity Primary T cells (Donor 6705) + 1 μg αHLA-cI + Donor SC09 NK cells (2:1) % S u r v i v a l ✱ GFP IdeStm 0 20 40 60 80 100 Complement Dependent Cytotoxicity Human Anti-HLA-ABC + 25% Complement (v/v) Donor SC07 Primary T Cell
Slide 9: Century is advancing a focused iPSC pipeline across cell types and targets
© 2025 9 9 Clinical IND - enabling Research Indications Targets Product Phase 3 Phase 2 Phase 1 B - cell - mediated autoimmune diseases CD19 CNTY - 101 iNK ( Allo - Evasion 1.0) B - cell - mediated diseases CD19 CNTY - 308 αβ iT ( Allo - Evasion 5.0) B - cell malignancies CD19 + CD22 CNTY - 341 iT (
Slide 10: CNTY-CAR-iNK cell therapy with Allo-Evasion 1.0
CNTY - 101 CAR - iNK cell therapy with Allo - Evasion 1.0
Slide 11: CNTY-101: CD19-targeted CAR-iNK product candidate
© 2025 11 11 Currently dosing patients in Phase 1 in autoimmune disorders https://www.centurytx.com/wp - content/uploads/ASGCT24 - CNTY - 101 - AI - Poster.pdf CNTY - 101: A CD19 - targeted CAR - iNK product candidate designed to provide precise control of drug exposure and enable repeat dosing CNTY
Slide 12: CNTY-101 is a differentiated autoimmune disease treatment
© 2025 12 12 Allogeneic iPSC • Available ‘off - the - shelf’ • No patient apheresis required • No manufacturing wait time • Batch - to - batch consistency • Platform enables lower COGs than donor - derived or autologous CNTY - 101 is a differentiated autoimmune disease treatment: Allogeneic iPSC CAR
Slide 13: Autoimmune disease patient populations and unmet need
© 2025 13 13 1. Tian Ann Rheum Dis 2023; Izmirly Arth Rheum 2021; Duarte - Garcia Ann Rheum Dis 2022; Hocaoglu Arth Rheum 2022; Smoyer - Tomic BMC Musculoskeletal Disorders 2012; Khoo Nat Rev Rheum 2023; Bendewald Arch Dermatol 2010; Bairkdar Rheumatology 2021; Fan J Manag Care Spec Pharm . 2020 2.
Slide 14: Opportunity for allogeneic cell therapies in autoimmune indications
© 2025 14 14 1. Mackensen Nature Medicine 2022 doi.org /10.1038/s41591 - 022 - 02017 - 5, Muller NEJM 2024 doi /full/10.1056/NEJMoa2308917, Muller ASH 2024 doi.org /10.1182/blood - 2024 - 194525, Sheikh Arthritis Rheumatol . 2024 2. Yu Arthritis Rheumatol . 2024; Goulding Arthritis Rheumatol . 2024,
Slide 15: CNTY-101 eliminates B cells with greater potency than primary CAR-T in vitro
© 2025 15 15 https://www.centurytx.com/wp - content/uploads/ASH_Chin_Natural - Killer - GD - Cells - Final.pdf ; Isolated B cells or CD19+ target cells were co - cultured with CNTY - 101 or primary CAR - T at several E:Ts in 96 - well U bottom plates in NKCM with assay harvested at 24h; Assay plates
Slide 16: CALiPSO-1 Phase 1 study in refractory autoimmune diseases
© 2025 16 16 SLE – Systemic Lupus Erythematosus; LN – Lupus Nephrits ; IIM – Idiopathic inflammatory Myopathy; dcSSc – Diffuse Cutaneous Systemic Sclerosis; DLT – Dose Limiting Toxicity; 2 cohorts open, one with CNTY - 101 as monotherapy and a second with CNTY - 101 supplemented with IL - 2 (1.5e6 I
Slide 17: ELiPSE-1 dose-escalating Phase 1 study in B-cell malignancies
© 2025 17 17 1. Standard lymphodepletion regimen: Fludarabine (30 mg/c/d) and cyclophosphamide IV (300 mg/m/d) for 3 days 2. Subjects who are assessed as stable disease or better may receive additional cycles of CNTY - 101 3. Subjects at DL4A did not receive IL - 2 on the day of CNTY - 101 infusio
Slide 18: ELiPSE-1 initial clinical experience in relapsed/refractory B-cell lymphoma
© 2025 18 18 Source: Company data available as of March 1, 2025 CNTY - 101 ELiPSE - 1 first - in - human study: Initial clinical experience in relapsed/refractory B - cell lymphoma validates Century’s IPSC platform Heavily pre - treated patient population (n=23 safety; n=22 efficacy) • Median 4 prio
Slide 19: CNTY-101 exposure increased with dose
© 2025 19 19 Source: Company data available as of March 7, 2025; Error bars show mean “ SD on original scale, subsequently log10 transformed. Due to log scale, low values are truncated at 1. All schedule B LDC+ cycles are included; S – Screen; LOB – Limit of Blank. CNTY - 101 exposure increased with
Slide 20: PK profile with and without lymphodepleting chemotherapy
© 2025 20 20 Infusion LDC • Lymphodepleting Chemotherapy (LDC) depleted patient NK/T cell counts and drove a transient spike of IL - 15 cytokine • By post - infusion day 8, NK/T cell counts, IL - 15 concentration returned to screening level • Similar PK profile observed for each CNTY - 101 infusion
Slide 21: CNTY-101 iNK cells traffic to lymph nodes
© 2025 21 21 Source: Company data as of March 7, 2025 CNTY - 101 cells were detected in lymph node tumor biopsies early post - treatment in Dose Level 3B and 4B CNTY - 101 iNK cells traffic to lymph nodes, observed more frequently at higher doses CAR TNFA IFNG CAR TNFA IFNG CAR CAR Day 10 Baseline C
Slide 22: Deep B-cell depletion and naive profile of re-emergent B cells
© 2025 22 22 Source: Company data, available as of March 7, 2024 CNTY - 101 treatment demonstrated deep B - cell depletion and was associated with naive non - class switched profile of re - emergent B - cells B - cell depletion Re - emergent B - cell profile • Rapid and effective depletion of circul
Slide 23: CNTY-CAR αβ-iT cell with Allo-Evasion 5.0
CNTY - 308 CAR αβ - iT cell with Allo - Evasion 5.0
Slide 24: Current CAR-T cell therapy market represents ~$4.5B worldwide sales
© 2025 24 24 1. 2024 worldwide sales, Evaluate Pharma 2025 - 04 - 15; (2) Prescribing information: CARVYKTI®, ABECMA®, YESCARTA®, BREYANZI®, KYMRIAH ®, TECARTUS®; (3) https://doi.org/10.1182/bloodadvances.2023012549 The current CAR - T cell therapy market represents ~$4.5B worldwide sales • All curr
Slide 25: CNTY-308 is an iPSC-derived CD19-targeted CAR-iT
© 2025 25 25 1. https://www.centurytx.com/wp - content/uploads/ASH_Heinze_iPSC - Derived - CD4 - CD8 - Final.pdf 2. Company data on file CNTY - 308 is an iPSC - derived CD19 - targeted CAR - iT intended for B - cell - mediated disease CD4+/CD8+ αβ iT - cell • CD19 - targeted CAR to target B - cells
Slide 26: Process designed to control the ratio of CD4+ to CD8+
© 2025 26 26 https://www.centurytx.com/wp - content/uploads/ASH_Heinze_iPSC - Derived - CD4 - CD8 - Final.pdf Century’s process is designed to control the ratio of CD4+ to CD8+ while expanding differentiating engineered CAR iPSC cells to αβ CAR - T cells Ending Viability Expansion from iPSCs ( - fol
Slide 27: iPSC-derived CAR-αβ T cells show characteristics similar to primary CAR-T cells
© 2025 27 27 CNTY - 308 1’ CAR - T Function ~2,000 ~3,000 IL - 2 secretion (pg/mL) No No Requires exogenous IL - 2/IL - 15 > 10 > 10 Repeat killing (rounds) 32 32 Persistence in blood (days) Yes Yes Tumor control after rechallenge ( in vivo) CNTY - 308 and 1’ CAR - T • Self - supports with own targe
Slide 28: iPSC-derived CAR-αβT cells display functional characteristics of adult primary T cells
© 2025 28 28 Effective T cell therapies require the generation of iPSC - CAR - T cells with three key in vitro cell functions Cytotoxicity: Effector function Cell expansion and persistence Therapeutic efficacy requires: Cytokine (IL2) production iPS - CAR - T 1’ CAR - T iPS - CAR - T 1’ CAR - T IL -
Slide 29: iPSC-CAR-T cells showed comparable activity to primary CAR-T in animal studies
© 2025 29 29 1e+06 1e+07 1e+08 1e+09 1e+10 0 10 20 30 40 Days Post−Effector Infusion L u m i n e s c e n c e ( l o g a x i s ) Group PBS only 1' CAR−T iPS−CAR−T Group 1: PBS only Group 2: 1' CAR−T Group 3: iPS−CAR−T 0 10 20 30 0 10 20 30 0 10 20 30 1e+07 1e+09 1e+11 Days Post−Effector Infusion L u m
Slide 30: Platform: iPSC cell foundry
Platform: iPSC cell foundry
Slide 31: Robust pre-clinical pipeline to address barriers in cellular therapies
© 2025 31 31 Century’s robust pre - clinical pipeline has potential to address critical barriers confronting cellular therapies Multiple iPSC - derived cells iPSC - enabled engineering solutions Opportunity across multiple diseases • Cytokine engineering to reduce or eliminate lymphodepletion •
Slide 32: Capability to make multiple cell types enables optimal matching
© 2025 32 32 Potential for long - lived memory , mediating immune surveillance GvHD risk, eliminated by knockout of T cell receptor (TCR) Greatest proliferative potential – potentially most useful for ongoing antigenic pressure Adaptive lymphocytes – capable of generating distinct functional attribu
Slide 33: Precision CRISPR MAD7-mediated sequential gene editing of iPSCs
© 2025 33 33 1. MAD7 Nuclease: https://www.inscripta.com/wp - content/uploads/2023/03/Liu - et - al - 2019 - Nature - Communications.pdf Precision CRISPR MAD7 - mediated sequential gene editing of iPSCs generates uniform product candidates Multiple gene edits (KO/KI) iPSC Engineered iPSC Master C el
Slide 34: Century platform and in-house manufacturing
© 2025 34 34 Century platform and in - house manufacturing: Pathway to scalable, profitable cell therapy Established in - house manufacturing from development to launch • Built - for - purpose 53,000 ft 2 cGMP facility • Key leaders each with 1 – 2 decades of cell therapy manufacturing expertise, fr
Slide 35: Estimated cash runway into 4Q27; enhanced resources to enable key milestones
Estimated cash runway into 4Q27; Enhanced resources to enable key value milestones Enhanced precl inical pipeline and platform aiming to expand and multiply cell therapy value • Prioritizing development activities for CNTY - 308 for B - cell - mediated diseases • Selective expansion to non - immune
Slide 36: Century Therapeutics
—) CENTURY _www.centurytx.com
Century Therapeutics — Investor Presentation (August 2025) on 6ix